类风湿-话题@MedSci

#类风湿#

751篇内容 | 7484人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1334170, encodeId=fb9013341e099, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=锝[99Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识, objectType=article, longId=183303, objectId=b423183303e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b423183303e4, replyNumber=0, likeNumber=17, createdTime=2019-11-21, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b423183303e4, moduleTitle=锝[99Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b423183303e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334169, encodeId=d15713341697a, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Ann Rheum Dis：类风湿性关节炎缓解后，以升高剂量策略持续停用英夫利昔单抗, objectType=article, longId=181702, objectId=2f81181e024b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f81181e024b, replyNumber=0, likeNumber=77, createdTime=2019-10-23, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f81181e024b, moduleTitle=Ann Rheum Dis：类风湿性关节炎缓解后，以升高剂量策略持续停用英夫利昔单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f81181e024b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334168, encodeId=b949133416894, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=PLoS Med：抗白介素-1治疗类风湿关节炎和2型糖尿病的疗效分析, objectType=article, longId=181625, objectId=a4e3181625d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4e3181625d6, replyNumber=0, likeNumber=93, createdTime=2019-10-21, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4e3181625d6, moduleTitle=PLoS Med：抗白介素-1治疗类风湿关节炎和2型糖尿病的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4e3181625d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334167, encodeId=51c7133416eec, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=2019 NICE诊断指南：类风湿性关节炎TNF-α抑制剂治疗监测（DG.36）, objectType=article, longId=180767, objectId=2da8180e67c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2da8180e67c7, replyNumber=0, likeNumber=16, createdTime=2019-10-10, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2da8180e67c7, moduleTitle=2019 NICE诊断指南：类风湿性关节炎TNF-α抑制剂治疗监测（DG.36）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2da8180e67c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334166, encodeId=fb601334166d5, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Arthritis Rheumatol：类风湿性关节炎患者炎症、心脏危险因素和用药对冠脉粥样硬化进展的影响, objectType=article, longId=179946, objectId=18b51e994644, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18b51e994644, replyNumber=0, likeNumber=55, createdTime=2019-09-25, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18b51e994644, moduleTitle=Arthritis Rheumatol：类风湿性关节炎患者炎症、心脏危险因素和用药对冠脉粥样硬化进展的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18b51e994644)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334165, encodeId=b80c13341656e, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=2019 HKSR共识建议：类风湿性关节炎的管理, objectType=article, longId=179897, objectId=0bce1e989788, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bce1e989788, replyNumber=0, likeNumber=14, createdTime=2019-09-24, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bce1e989788, moduleTitle=2019 HKSR共识建议：类风湿性关节炎的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bce1e989788)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334164, encodeId=528d1334164b4, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Clinica Chimica Acta：唐氏综合症患者类风湿因子的患病率增加，但抗环瓜氨酸肽自身抗体却未增加？, objectType=article, longId=179563, objectId=485f1e9563e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=485f1e9563e9, replyNumber=0, likeNumber=75, createdTime=2019-09-18, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=485f1e9563e9, moduleTitle=Clinica Chimica Acta：唐氏综合症患者类风湿因子的患病率增加，但抗环瓜氨酸肽自身抗体却未增加？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=485f1e9563e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334163, encodeId=ca76133416315, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Ann Rheum Dis：类风湿性关节炎病程和既往使用DMARDs对治疗结局的影响, objectType=article, longId=178120, objectId=f7071e8120be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7071e8120be, replyNumber=0, likeNumber=52, createdTime=2019-08-24, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7071e8120be, moduleTitle=Ann Rheum Dis：类风湿性关节炎病程和既往使用DMARDs对治疗结局的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f7071e8120be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334162, encodeId=7c3c1334162b4, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Ann Rheum Dis：类风湿性关节炎患者病假或工作失能的不同规定, objectType=article, longId=178019, objectId=65ff1e80199b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=65ff1e80199b, replyNumber=0, likeNumber=60, createdTime=2019-08-22, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=65ff1e80199b, moduleTitle=Ann Rheum Dis：类风湿性关节炎患者病假或工作失能的不同规定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=65ff1e80199b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334161, encodeId=f1211334161cf, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, objectType=article, longId=177845, objectId=6bec1e7845da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bec1e7845da, replyNumber=0, likeNumber=47, createdTime=2019-08-19, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bec1e7845da, moduleTitle=FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6bec1e7845da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334160, encodeId=2dae1334160a6, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=JAMA：Filgotinib治疗难治性活动性类风湿关节炎, objectType=article, longId=176135, objectId=33ad1e61350f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33ad1e61350f, replyNumber=0, likeNumber=73, createdTime=2019-07-26, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33ad1e61350f, moduleTitle=JAMA：Filgotinib治疗难治性活动性类风湿关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33ad1e61350f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334159, encodeId=68e7133415911, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=类风湿性关节炎新药「塞妥珠单抗」在中国获批上市, objectType=article, longId=175608, objectId=f0901e560863, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0901e560863, replyNumber=0, likeNumber=81, createdTime=2019-07-18, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0901e560863, moduleTitle=类风湿性关节炎新药「塞妥珠单抗」在中国获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0901e560863)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334158, encodeId=15f21334158d2, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=JCLA：类风湿性关节炎患者白蛋白- dNLR评分与疾病活动程度的关系, objectType=article, longId=175510, objectId=75fa1e551072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=75fa1e551072, replyNumber=0, likeNumber=64, createdTime=2019-07-16, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=75fa1e551072, moduleTitle=JCLA：类风湿性关节炎患者白蛋白- dNLR评分与疾病活动程度的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=75fa1e551072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334157, encodeId=b395133415e39, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较, objectType=article, longId=175232, objectId=9d501e52321e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9d501e52321e, replyNumber=0, likeNumber=75, createdTime=2019-07-13, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9d501e52321e, moduleTitle=Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9d501e52321e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334156, encodeId=bc57133415692, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, objectType=article, longId=175230, objectId=0b961e52306e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b961e52306e, replyNumber=0, likeNumber=91, createdTime=2019-07-13, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b961e52306e, moduleTitle=Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b961e52306e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334155, encodeId=a4cc1334155d5, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=GSK抗GM-CSF单抗otilimab治疗类风湿性关节炎正在开展3期临床研究, objectType=article, longId=174900, objectId=d1021e49006a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1021e49006a, replyNumber=0, likeNumber=69, createdTime=2019-07-07, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1021e49006a, moduleTitle=GSK抗GM-CSF单抗otilimab治疗类风湿性关节炎正在开展3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1021e49006a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334154, encodeId=8120133415417, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=J Rheumatol：阿巴西普是否会增加类风湿性关节炎的术后不良事件？, objectType=article, longId=174426, objectId=f0db1e442602, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0db1e442602, replyNumber=0, likeNumber=0, createdTime=2019-06-30, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0db1e442602, moduleTitle=J Rheumatol：阿巴西普是否会增加类风湿性关节炎的术后不良事件？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0db1e442602)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334153, encodeId=5a971334153f2, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=J Rheumatol：利妥昔单抗治疗系统性类风湿性血管炎, objectType=article, longId=174425, objectId=bc161e442595, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc161e442595, replyNumber=0, likeNumber=65, createdTime=2019-06-30, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc161e442595, moduleTitle=J Rheumatol：利妥昔单抗治疗系统性类风湿性血管炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc161e442595)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334152, encodeId=4eb2133415207, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=J Rheumatol：类风湿性关节炎骨科手术的趋势—17年全国住院患者登记结果, objectType=article, longId=174423, objectId=89711e4423c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89711e4423c1, replyNumber=0, likeNumber=108, createdTime=2019-06-30, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89711e4423c1, moduleTitle=J Rheumatol：类风湿性关节炎骨科手术的趋势—17年全国住院患者登记结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=89711e4423c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1334151, encodeId=2647133415187, content=<a href='/topic/show?id=5306e6164b6' target=_blank style='color:#2F92EE;'>#类风湿#</a>, objectTitle=Ann Rheum Dis：对培化舍珠单抗反应不良的类风湿性关节炎中，bimekizumab的疗效和安全性, objectType=article, longId=167998, objectId=9e5216e998c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e5216e998c7, replyNumber=0, likeNumber=0, createdTime=2019-06-12, rootId=0, userName=ms4964546379600229, userId=6ff22500098, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e5216e998c7, moduleTitle=Ann Rheum Dis：对培化舍珠单抗反应不良的类风湿性关节炎中，bimekizumab的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e5216e998c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

类风湿

2020-05-29

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

锝[99Tc]亚甲基二膦酸盐注射液治疗类风湿关节炎专家共识

2019-11-21

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Ann Rheum Dis：类风湿性关节炎缓解后，以升高剂量策略持续停用英夫利昔单抗

2019-10-23

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

PLoS Med：抗白介素-1治疗类风湿关节炎和2型糖尿病的疗效分析

2019-10-21

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

2019 NICE诊断指南：类风湿性关节炎TNF-α抑制剂治疗监测（DG.36）

2019-10-10

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Arthritis Rheumatol：类风湿性关节炎患者炎症、心脏危险因素和用药对冠脉粥样硬化进展的影响

2019-09-25

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

2019 HKSR共识建议：类风湿性关节炎的管理

2019-09-24

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Clinica Chimica Acta：唐氏综合症患者类风湿因子的患病率增加，但抗环瓜氨酸肽自身抗体却未增加？

2019-09-18

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Ann Rheum Dis：类风湿性关节炎病程和既往使用DMARDs对治疗结局的影响

2019-08-24

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Ann Rheum Dis：类风湿性关节炎患者病假或工作失能的不同规定

2019-08-22

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

FDA批准JAK抑制剂Rinvoq用于中度至重度类风湿性关节炎

2019-08-19

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

JAMA：Filgotinib治疗难治性活动性类风湿关节炎

2019-07-26

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

类风湿性关节炎新药「塞妥珠单抗」在中国获批上市

2019-07-18

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

JCLA：类风湿性关节炎患者白蛋白- dNLR评分与疾病活动程度的关系

2019-07-16

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Arthritis Rheumatol：培化舍珠单抗、阿巴西普和英夫利昔单抗生物仿制药治疗类风湿性关节炎的疗效比较

2019-07-13

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Arthritis Rheumatol：Upadacitinib治疗甲氨蝶呤反应不足类风湿性关节炎的3期试验

2019-07-13

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

GSK抗GM-CSF单抗otilimab治疗类风湿性关节炎正在开展3期临床研究

2019-07-07

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

J Rheumatol：阿巴西普是否会增加类风湿性关节炎的术后不良事件？

2019-06-30

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

J Rheumatol：利妥昔单抗治疗系统性类风湿性血管炎

2019-06-30

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

J Rheumatol：类风湿性关节炎骨科手术的趋势—17年全国住院患者登记结果

2019-06-30

ms4964546379600229 (审核中...)

前往app查看评论内容

#类风湿#

Ann Rheum Dis：对培化舍珠单抗反应不良的类风湿性关节炎中，bimekizumab的疗效和安全性

2019-06-12

科室
- - 订阅+
  - 更多科室
工具
服务